REMEGEN (09995) saw its stock price soar by 7.41% during Tuesday's trading session, reaching HK$118.50 with a trading volume of HK$542 million. This significant uptick appears to be driven by two key developments in the company's pipeline and research activities.

The primary catalyst for the stock's surge is the news that REMEGEN's ophthalmology innovative drug, Iledefusp α (RC28), has filed for market approval with the Chinese drug regulator for the treatment of diabetic macular edema (DME). This filing comes on the heels of a substantial agreement reached in August with Santen Pharmaceutical's subsidiary, granting exclusive rights for Iledefusp α in several Asian markets, valued at RMB 1.295 billion.

Adding to investor optimism, REMEGEN announced its strong presence at the upcoming 2025 European Society for Medical Oncology (ESMO) Annual Congress. The company will present 11 original research results, including a Late Breaking Abstract on the Phase III clinical study of Vedicitumab combination therapy for first-line urothelial cancer. This showcase of REMEGEN's diverse oncology portfolio, covering multiple tumor types and treatment strategies, further underscores the company's robust pipeline and potential for future growth.